Japan has granted the world's first regulatory approval for the commercial sale of iPS cell-based medical treatments. This historic milestone, supported by extensive research in PubMed, transitions induced pluripotent stem cell technology from the laboratory to the clinic, positioning Japan as the global leader in regenerative medicine.
Jessy·
Japan has granted the world's first commercial approvals for medical products based on reprogrammed human cells (iPS cells), bringing a Nobel-winning discovery to the mass market. This regulatory milestone paves the way for advanced regenerative therapies for degenerative diseases. The decision highlights Japan's leadership in the field and is expected to accelerate global cell therapy adoption.
Williams·
Japan has granted the world's first regulatory approval for a medical product derived from induced pluripotent stem cells (iPSCs), a technology that won the Nobel Prize in 2012. This milestone enables the mass production of standardized 'off-the-shelf' cell therapies, starting with cancer treatments. Analysts expect this move to trigger a global surge in regenerative medicine investment and set new regulatory standards for the US and Europe.
Williams·